Business
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharma
About this update from Korro Bio, Inc.
[{"type":"image","alt":"Korro Bio, Inc.","displaySize":"","headline":null,"caption":"Korro Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rSREgeXHJL6TSO0VlFoJTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e","width":300,"height":56}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028","length":100,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":395,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.","length":346,"tagName":"p"},{"type":"text","content":"“This past year and in particular, the fourth quarter proved to be an important period for the company as we continued our mission to develop treatments for debilitating diseases using our novel RNA editing platform,” commented Ram Aiyar, Ph.D., Chief Executive Officer and President of Korro Bio. “We entered 2026 with a great deal of momentum, and with the recent closing of a private placement financing, are now well positioned to achieve our clinical and corporate growth objectives.”","length":489,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Highlights and Recent Developments:","length":55,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nominated KRRO-121 for clinical development for the treatment of hyperammonemia...